Clara Hwang, MD, discusses the utility of antiandrogens in patients with metastatic prostate cancer.
Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses the utility of antiandrogens in patients with metastatic prostate cancer.
In the randomized, phase III TITAN study, investigators examined the role of the androgen receptor (AR) antagonist apalutamide (Erleada) in patients with metastatic castration-sensitive prostate cancer. Results showed that this is another therapy option that, when given in combination with androgen suppression, can provide benefit to patients, says Hwang.
Enzalutamide (Xtandi) is another AR antagonist that was examined in 2 trials that presented results: ARCHES and ENZAMET. Both studies showed that the addition of enzalutamide to androgen suppression therapy can also improve survival in patients with hormone-sensitive prostate cancer. These trials show that enzalutamide can also be considered for this patient population, concludes Hwang.